Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has raised £620,000 through convertible loan notes to support the clinical trial of its CAR-T cell therapy, HG-CT-1, targeting relapsed or refractory acute myeloid leukemia. This funding, backed by a small investor group, reflects confidence in the company’s strategy and will bolster its financial position, allowing it to continue advancing its clinical development efforts.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 65,181
Technical Sentiment Signal: Buy
Current Market Cap: £25.05M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.